Macklis Roger M
Cleveland Clinic Lerner College of Medicine and Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
Semin Radiat Oncol. 2007 Jul;17(3):176-83. doi: 10.1016/j.semradonc.2007.02.003.
Radioimmunotherapy (RIT) represents a relatively new antibody-based radiopharmaceutical treatment for patients with various kinds of tumors. Although the field has a long history of preclinical and clinical investigations using many different agents, to date, only 2 of these immunologically targeted radiopharmaceuticals have been cleared for commercial sale. Both of these agents ((90)Y-ibritumomab tiuxetan or "Zevalin" [Biogen-Idec, Boston, MA] and (131)I-tositumomab or "Bexxar" [GlaxoSmithKline Research, Triangle Park, NC]) are directed against the CD20 surface antigen found on normal mature B cells and greater than 95% of B-cell non-Hodgkin lymphoma (NHL). Both compounds produce similar impressive clinical outcomes (approximately 20%-40% complete response rates and 60%-80% overall response rates for patients with indolent B-cell NHL). Current protocol-based investigations of anti-CD20 RIT relate to new clinical uses and new CD20(+) targets.
放射免疫疗法（RIT）是一种相对较新的、基于抗体的放射性药物治疗方法，用于治疗各类肿瘤患者。尽管该领域使用多种不同药物进行临床前和临床研究的历史悠久，但迄今为止，这些免疫靶向放射性药物中只有两种已获批商业销售。这两种药物（（90）Y-伊布替尼单抗替曲膦或“泽瓦林”[百健艾迪公司，马萨诸塞州波士顿]和（131）I-托西莫单抗或“贝沙罗汀”[葛兰素史克研究公司，北卡罗来纳州三角研究园]）均针对正常成熟B细胞以及超过95%的B细胞非霍奇金淋巴瘤（NHL）中发现的CD20表面抗原。这两种化合物产生了相似的显著临床效果（惰性B细胞NHL患者的完全缓解率约为20%-40%，总缓解率为60%-80%）。目前基于方案的抗CD20 RIT研究涉及新的临床用途和新的CD20(+)靶点。
